Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00593463 · ClinicalTrials.gov registry record · Phase 1
Drug Discrimination in Methadone-Maintained Humans Study 1
A Phase 1 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00593463 is a Phase 1 study that has completed, run by University of Arkansas. The registered enrollment target is 40 participants.
The verdict
NCT00593463, a Phase 1 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study involves giving psychoactive drugs intramuscularly (injected into the muscle of the upper arm or the hip) and/or orally, and measuring the subject's ability to tell the difference between one drug and another, as well as measuring the effects of the drugs on mood, physiology (e.g., heart rate, blood pressure, respiration rate) and behavior. Each subject will receive 2-4 of the listed interventions.
Interventions
- DRUG Gabapentin
- DRUG Naloxone
- DRUG Diltiazem
- DRUG Cycloserine
- DRUG Isradipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-09 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00593463
The ClinicalTrials.gov registry entry for NCT00593463 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Gabapentin is the first listed.
NCT00593463 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00593463 about?
NCT00593463 is a clinical study titled "Drug Discrimination in Methadone-Maintained Humans Study 1". This study involves giving psychoactive drugs intramuscularly (injected into the muscle of the upper arm or the hip) and/or orally, and measuring the subject's ability to tell the difference between one drug and another, as well as measuring the effects of the drugs on mood, physiology (e.g., heart ...
What is the current status of trial NCT00593463?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2006-09. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00593463?
The interventions under investigation include: Gabapentin (DRUG), Naloxone (DRUG), Diltiazem (DRUG), Cycloserine (DRUG), Isradipine (DRUG).
Who is sponsoring clinical trial NCT00593463?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.